314-50-1

Orotidine is a metabolite of Orotic Acid (O691500); a compound used in the preparation of therapeutic agents for chronic obstructive pulmonary disease (COPD) treatment.

ChEBI: A nucleoside formed by attaching orotic acid to a ribose ring via a beta1N(1)-glycosidic bond.

This water-soluble ribonucleoside (FWfree-acid = 288.21 g/mol; CAS 314-50- 1; lmax of 267 nm in 0.1 N HCl (e = 9570 cm–1M–1; another report lists 9800) and 265 nm in 0.1 N methanolic NaOH (e = 8960 cm–1M–1; another report lists 7800)), first observed in Neurospora crassa, is also foound in the urine of cancer patients treated with 6-azauridine, Orotidine is most likely formed from OMP, its 5’-monophosphate ester and the direct precursor of UMP. Orotidine is readily hydrolyzed in dilute mineral acids. Target(s): orotate phosphoribosyltransferase; orotidine-5’-phosphate decarboxylase.

Human Endogenous Metabolite

Store at -20°C